Federal Register #2026-09292

NIH/NICHD Licensing Opportunity: T-cell Immunotherapy Invention Targeting SIT1, LAX1, and TRAT1

The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is seeking licensees for a government-owned T-cell immunotherapy invention. - Government Buyer: - Department of Health and Human Services - National Institutes of Health (NIH) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) - OEMs and Vendors: - No commercial OEMs or vendors; technology is government-owned - Products/Services Requested: - Licensing and further development of a T-cell immunotherapy invention - Invention targets inhibitory transmembrane adapter proteins: SIT1, LAX1, and TRAT1 - Focus on enhancing tumor reactivity of T cells for treatment of cancer, infectious diseases, and autoimmune diseases - Intellectual property assigned to the U.S. government (NIH Reference Number E0042024) - Unique or Notable Requirements: - Opportunity is for licensing and therapeutic development, not product purchase - Invention is at pre-clinical validation stage - Competitive advantages include enhanced T-cell cytotoxicity and ability to overcome immunosuppression in the tumor microenvironment - Targeted for organizations interested in oncology and immunology therapeutic development

Description

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees to develop inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy. This immunotherapy aims to treat cancer, infectious diseases, and autoimmune diseases by enhancing T cell cytotoxicity against tumor cells. The invention involves targeting proteins SIT1, LAX1, and TRAT1, which inhibit T cell activation, with pre-clinical validation ongoing. Licensing opportunities are available to further develop these therapeutic approaches.

View original listing